Atossa Therapeutics (ATOS) 10-Q 13 May 20 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 08, 2020
Document Information [Line Items]
Entity Registrant Name	ATOSSA THERAPEUTICS, INC.
Entity Central Index Key	0001488039
Trading Symbol	atos
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		9,208,458
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common Stock, $0.18 par value

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 9,351,141	$ 12,581,136
Restricted cash	110,000	110,000
Prepaid expenses	1,337,120	862,344
Research and development tax rebate receivable	734,340	739,656
Other current assets	134,519	26,130
Total current assets	11,667,120	14,319,266
Furniture and equipment, net	29,734	34,350
Intangible assets, net	60,833	68,542
Right-of-use asset	37,397	50,479
Other assets	17,218	17,218
Total Assets	11,812,302	14,489,855
Current liabilities
Accounts payable	356,252	293,171
Accrued expenses	52,474	77,888
Payroll liabilities	466,383	899,420
Lease liability	29,385	39,371
Other current liabilities	3,458	12,892
Total current liabilities	907,952	1,322,742
Long term liabilities
Lease liability long term	8,013	11,108
Total Liabilities	915,965	1,333,850
Commitments and contingencies (Note 12)
Stockholders' equity
Preferred stock - $0.001 par value; 10,000,000 shares authorized; 671 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively	1	1
Additional paid-in capital - Series B convertible preferred stock	670,999	670,999
Common stock - $0.18 par value; 175,000,000 shares authorized, and 9,130,984 shares issued and outstanding, as of March 31, 2020 and December 31, 2019, respectively	1,643,565	1,643,565
Additional paid-in capital	105,600,232	104,912,480
Accumulated deficit	(97,018,460)	(94,071,040)
Total Stockholders' Equity	10,896,337	13,156,005
Total Liabilities and Stockholders' Equity	$ 11,812,302	$ 14,489,855

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, issued (in shares)	671	671
Preferred stock, outstanding (in shares)	671	671
Common stock, par value (in dollars per share)	$ 0.18	$ 0.18
Common stock, authorized (in shares)	175,000,000	175,000,000
Common stock, issued (in shares)	9,130,984	9,130,984
Common stock, outstanding (in shares)	9,130,984	9,130,984

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating expenses
Research and development	$ 938,620	$ 1,451,236
General and administrative	1,998,389	2,613,093
Total operating expenses	2,937,009	4,064,329
Operating loss	(2,937,009)	(4,064,329)
Other expense	(10,411)	(8,978)
Loss before income taxes	(2,947,420)	(4,073,307)
Income taxes
Net loss	$ (2,947,420)	$ (4,073,307)
Loss per common share - basic and diluted (in dollars per share)	$ (0.32)	$ (0.62)
Weighted average shares outstanding - basic and diluted (in shares)	9,130,984	6,565,514

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Preferred Stock Additional Paid-in Capital [Member]Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Common Stock Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018	2,379		5,846,552
Balance at Dec. 31, 2018	$ 2	$ 2,378,997	$ 1,052,372	$ 82,204,902	$ (76,831,263)	$ 8,805,010
Issuance of common stock upon warrant exercise (in shares)			2,799,188			2,800,000
Issuance of common stock upon warrant exercise			$ 503,854	10,832,856		$ 11,336,710
Conversion of convertible preferred stock to common stock (in shares)	1,677		(476,431)
Conversion of convertible preferred stock to common stock	$ 1	1,676,998	$ (85,753)	(1,591,246)
Conversion of convertible preferred stock to common stock	(1)	(1,676,998)	85,753	1,591,246
Compensation cost for stock options granted				275,833		275,833
Reclassification of stock-based compensation liability upon option cancellation				3,151,944		3,151,944
Net loss					(4,073,307)	(4,073,307)
Balance (in shares) at Mar. 31, 2019	702		9,122,171
Balance at Mar. 31, 2019	$ 1	701,999	$ 1,641,979	98,056,781	(80,904,570)	19,496,190
Balance (in shares) at Dec. 31, 2019	671		9,130,984
Balance at Dec. 31, 2019	$ 1	670,999	$ 1,643,565	104,912,480	(94,071,040)	13,156,005
Compensation cost for stock options granted				687,752		687,752
Net loss					(2,947,420)	(2,947,420)
Balance (in shares) at Mar. 31, 2020	671		9,130,984
Balance at Mar. 31, 2020	$ 1	$ 670,999	$ 1,643,565	$ 105,600,232	$ (97,018,460)	$ 10,896,337

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	1 Months Ended	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		$ (2,947,420)	$ (4,073,307)
Adjustments to reconcile net loss to net cash used in operating activities
Compensation cost for stock options granted		687,752	275,833
Depreciation and amortization		12,326	13,983
Change in fair value of stock-based compensation liability			1,741,919
Changes in operating assets and liabilities:
Prepaid expenses		(474,776)	(325,635)
Research and development tax rebate receivable		5,316	280,242
Other assets		(108,389)	2,985
Accounts payable		63,081	110,642
Accrued expenses		(25,414)	(102,230)
Payroll liabilities		(433,037)	(43,312)
Other current liabilities		(9,434)	(30,076)
Net cash used in operating activities		(3,229,995)	(2,148,956)
CASH FLOWS FROM INVESTING ACTIVITY
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITY
Proceeds from exercise of warrants	$ 11,300,000	0	11,336,710
Net cash provided by financing activities			11,336,710
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH		(3,229,995)	9,187,754
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE		12,691,136	10,490,493
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	19,678,247	9,461,141	19,678,247
SUPPLEMENTAL DISCLOSURES
Cash and cash equivalents	19,568,247	9,351,141	19,568,247
Restricted cash	110,000	110,000	110,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	$ 19,678,247	9,461,141	19,678,247
NONCASH INVESTING AND FINANCING ACTIVITIES
Reclassification of stock-based liability awards to equity upon cancellation			$ 3,151,944

Note 1 - Nature of Operations

Note 1 - Nature of Operations	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Nature of Operations [Text Block]	NOTE 1: On January 6, 2020, Atossa Therapeutics, Inc. (the “Company”) was incorporated on April 30, 2009, December 31. 19" Impact of the Novel Coronavirus The continued spread of the COVID- 19 may third H201 19 may 19 may may not may 19 may not 19 19 may 19 not third In response to the Coronavirus pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law on March 27, 2020. no three March 31, 2020. may

Note 2 - Going Concern

Note 2 - Going Concern	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2: The Company has incurred net losses and negative operating cash flows since inception. For the three March 31, 2020, $2.9 $3.2 March 31, 2020, $9.4 $10.8 not four seven The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. As the Company is currently not no 19 may may not

Note 3 - Summary of Accounting

Note 3 - Summary of Accounting Policies	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	NOTE 3: Basis of Presentation: The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10 10 01 X. not no 10 December 31, 2019. not In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three March 31, 2020, not may December 31, 2020. Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Research and Development Expense: Research and development ("R&D") costs are generally expensed as incurred. R&D expenses include, for example, manufacturing expenses for our drugs under development, expenses associated with clinical trials and associated salaries and benefits. R&D expenses also include an estimated allocation of the CEO's salary and related benefits including non-cash stock-based compensation expense based on time devoted to R&D. Recently Adopted Accounting Pronouncements: On January 1, 2020, No. 2018 13, Fair Value Measurement (Topic 820 820, 3 no

Note 4 - Restricted Cash

Note 4 - Restricted Cash	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Restricted Assets Disclosure [Text Block]	NOTE 4: The Company's restricted cash balance of $110,000 March 31, 2020 December 31, 2019,

Note 5 - Prepaid Expenses

Note 5 - Prepaid Expenses	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Prepaid Expenses [Text Block]	NOTE 5: Prepaid expenses consisted of the following: As of March 31, As of December 31, 2020 2019 Prepaid research and development $ 712,387 $ 507,733 Prepaid insurance 280,098 222,476 Professional services 278,298 108,850 Financial exchange fees 32,250 - Retainer and security deposits 14,218 14,218 Prepaid rent 17,952 4,275 Other 1,917 4,792 Total prepaid expenses $ 1,337,120 $ 862,344

Note 6 - Research and Developme

Note 6 - Research and Development Tax Rebate Receivable	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Research and Development Tax Rebate Receivable [Text Block]	NOTE 6: On May 23, 2017, 1 2 $0.435 three March 31, 2020 2019, $133,400 $34,700, March 31, 2020 December 31, 2019, $734,340 $739,656,

Note 7 - Payroll Liabilities

Note 7 - Payroll Liabilities	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	NOTE 7: Payroll liabilities consisted of the following: As of March 31, As of December 31, 2020 2019 Accrued bonuses $ 203,779 $ 646,064 Accrued vacation 179,533 170,820 Accrued payroll 83,071 82,536 Total payroll liabilities $ 466,383 $ 899,420

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 8: The Company is authorized to issue a total of 185,000,000 175,000,000 $0.18 10,000,000 $0.001 750,000 $0.001 4,000 $0.001 25,000 $0.001 No no March 31, 2020 December 31, 2019. Equity Distribution Agreement On February 7, 2020, $0.18 $5,000,000. 3.0% no may may May 8, 2020, 68,098 $150,253. Warrants As of March 31, 2020, 1,070,028 $4.05 May 30, 2022. There were no three March 31, 2020. three March 31, 2019, $11.3 2.8 2.8 Conversion of Series B Convertible Preferred Stock There were no three March 31, 2020. three March 31, 2019, 1,677 476,431 284

Note 9 - Net Loss Per Share

Note 9 - Net Loss Per Share	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 9: Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back any convertible preferred dividends. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding. Potential common shares consist of potential future exercises of outstanding stock options and common stock warrants. Because the inclusion of potential common shares would be anti-dilutive for all periods presented, they have been excluded from the calculation. The following table summarizes the Company’s calculation of net loss per common share: Three Months Ended March 31, 2020 2019 Numerator Net loss attributable to common shareholders $ (2,947,420 ) $ (4,073,307 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 9,130,984 6,565,514 Net loss per share of common stock, basic and diluted: $ (0.32 ) $ (0.62 ) The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share, because including them would be anti-dilutive: Three Months Ended March 31, 2020 2019 Options to purchase common stock 4,308,383 783,383 Series B convertible preferred stock 190,617 458,994 Warrants to purchase common stock 1,070,028 3,369,468 5,569,028 4,611,845

Note 10 - Income Taxes

Note 10 - Income Taxes	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 10: Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No March 31, 2020 December 31, 2019,

Note 11 - Concentration of Cred

Note 11 - Concentration of Credit Risk	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE 11: Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. March 31, 2020 December 31, 2019, $8,967,650 $12,316,429

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 12: Lease Commitments The Company evaluates all contractual agreements at inception to determine if they contain a lease. Lease liabilities are measured at present value of lease payments not The Company's operating lease assets consist of an office lease and a copier system lease. Our office lease expires in August 2020 October 2021. None three March 31, 2020 2019, $13,300 $12,900, March 31, 2020, 9 12%. As of March 31, 2020, $29,500 $12,400 2020 2021, March 31, 2020 2019, $4,500 $12,900, three March 31, 2020 2019, $14,700 $14,600, Litigation and Contingencies We are subject to legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should not

Note 13 - Stock Based Compensat

Note 13 - Stock Based Compensation	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	NOTE 13: Stock Option and Incentive Plan On March 24, 2020, 2020 2020 No may 2020 10 On September 28, 2010, 2010 2010 may 2010 September 2020. 5,556 2010 May 18, 2016, 11,111 2010 May 9, 2018, 125,000 2010 April 12, 2018, 500,000 2010 May 16, 2019 3,600,000 The following table presents the automatic additions to the 2010 2010 January 1, Number of 2012 2,502 2013 2,871 2014 4,128 2015 5,463 2016 7,257 2017 12,623 2018 106,076 2019 233,862 2020 365,239 Total additional shares 740,021 The Company did not three March 31, 2020 2019. No three March 31, 2020 2019. 676,669 2010 March 31, 2020. Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $687,752 $275,833 three March 31, 2020 2019, Three Months Ended March 31, 2020 2019 General and administrative $ 483,000 $ 224,676 Research and development 204,752 51,157 Total stock compensation expense $ 687,752 $ 275,833 Options issued and outstanding as of March 31, 2020, 2010 three Number of Weighted- Weighted- Aggregate Outstanding as of January 1, 2020 4,308,383 $ 3.44 - Granted - - - Forfeited - - - Expired - - - Outstanding as of March 31, 2020 4,308,383 3.44 8.80 $ - Exercisable as of March 31, 2020 3,832,000 3.58 8.80 $ - Vested and expected to vest 4,308,383 $ 3.44 8.80 $ - At March 31, 2020, 476,383 $953,046. 0.59 Liability Options On June 27, 2018, 2,300,000 700,000 2010 2010 January 13, 2019, Compensation costs associated with the Liability Options were initially recognized, based on the grant-date fair values of these options, over the requisite or vesting period for time-based options or when it is probable the performance criteria were achieved for options that vest based on performance. Compensation cost was remeasured each period based on the market value of our underlying stock until award vesting or settlement. At the time of cancellation, the fair value of Liability Options at January 13, 2019, January 13, 2019 Risk free interest rate 2.53 % Expected term (in years) 4.50-5.00 Stock price $ 1.36 Dividend yield - % Expected volatility 121.0-123.0 % As a result of the cancellation of these options in the first 2019, $1,741,919, Period Ended March 31, 2019 General and administrative $ 1,074,183 Research and development 667,736 Total stock compensation expense $ 1,741,919 Also on January 13, 2019, 2,300,000 800,000 “2019 2019 $1.36 not 2010 January 13, 2019, 2019 2010 2019 not 2010 2018 2019 not 2019 The above actions were unanimously approved by the disinterested members of the Board of Directors. The above actions were intended to eliminate the Company’s potential liability associated with the net cash exercise provision of the Liability Options, and to allow the stockholders of the Company the opportunity to vote on the Amended Plan, which includes shares issuable upon exercise of the 2019 May 16, 2019, 2019 Accounting Treatment Awards offered under a plan that are subject to shareholder approval are not may not 2019 2019 not 718. not no January 13, 2019, $1,741,919 2018 $3,151,944 May 16, 2019, 2019 2019 718 June 30, 2019. $4,959,277 second 2019 2019

Note 14 - Subsequent Event

Note 14 - Subsequent Event	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 14: On April 9, 2020, “2020 1,500,000 195,000 2010 1,305,000 2020 590,000 195,000 2010 395,000 2020 The 2020 $1.48 2020 two 50% 2020 2020 2020 not 2020 not one The above actions were unanimously approved by the Compensation Committee of the Board of Directors.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation: The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10 10 01 X. not no 10 December 31, 2019. not In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three March 31, 2020, not may December 31, 2020.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expense: Research and development ("R&D") costs are generally expensed as incurred. R&D expenses include, for example, manufacturing expenses for our drugs under development, expenses associated with clinical trials and associated salaries and benefits. R&D expenses also include an estimated allocation of the CEO's salary and related benefits including non-cash stock-based compensation expense based on time devoted to R&D.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements: On January 1, 2020, No. 2018 13, Fair Value Measurement (Topic 820 820, 3 no

Note 5 - Prepaid Expenses (Tabl

Note 5 - Prepaid Expenses (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	As of March 31, As of December 31, 2020 2019 Prepaid research and development $ 712,387 $ 507,733 Prepaid insurance 280,098 222,476 Professional services 278,298 108,850 Financial exchange fees 32,250 - Retainer and security deposits 14,218 14,218 Prepaid rent 17,952 4,275 Other 1,917 4,792 Total prepaid expenses $ 1,337,120 $ 862,344

Note 7 - Payroll Liabilities (T

Note 7 - Payroll Liabilities (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	As of March 31, As of December 31, 2020 2019 Accrued bonuses $ 203,779 $ 646,064 Accrued vacation 179,533 170,820 Accrued payroll 83,071 82,536 Total payroll liabilities $ 466,383 $ 899,420

Note 9 - Net Loss Per Share (Ta

Note 9 - Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, 2020 2019 Numerator Net loss attributable to common shareholders $ (2,947,420 ) $ (4,073,307 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 9,130,984 6,565,514 Net loss per share of common stock, basic and diluted: $ (0.32 ) $ (0.62 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended March 31, 2020 2019 Options to purchase common stock 4,308,383 783,383 Series B convertible preferred stock 190,617 458,994 Warrants to purchase common stock 1,070,028 3,369,468 5,569,028 4,611,845

Note 13 - Stock Based Compens_2

Note 13 - Stock Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	January 1, Number of 2012 2,502 2013 2,871 2014 4,128 2015 5,463 2016 7,257 2017 12,623 2018 106,076 2019 233,862 2020 365,239 Total additional shares 740,021
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Weighted- Weighted- Aggregate Outstanding as of January 1, 2020 4,308,383 $ 3.44 - Granted - - - Forfeited - - - Expired - - - Outstanding as of March 31, 2020 4,308,383 3.44 8.80 $ - Exercisable as of March 31, 2020 3,832,000 3.58 8.80 $ - Vested and expected to vest 4,308,383 $ 3.44 8.80 $ -
Liability Options [Member]
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	January 13, 2019 Risk free interest rate 2.53 % Expected term (in years) 4.50-5.00 Stock price $ 1.36 Dividend yield - % Expected volatility 121.0-123.0 %
Share-based Payment Arrangement, Option [Member]
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, 2020 2019 General and administrative $ 483,000 $ 224,676 Research and development 204,752 51,157 Total stock compensation expense $ 687,752 $ 275,833 Period Ended March 31, 2019 General and administrative $ 1,074,183 Research and development 667,736 Total stock compensation expense $ 1,741,919

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Net Income (Loss) Attributable to Parent, Total	$ (2,947,420)	$ (4,073,307)
Net Cash Provided by (Used in) Operating Activities, Total	(3,229,995)	(2,148,956)
Cash and Cash Equivalents, at Carrying Value, Ending Balance	9,351,141	$ 19,568,247	$ 12,581,136
Working Capital	$ 10,800,000

Note 4 - Restricted Cash (Detai

Note 4 - Restricted Cash (Details Textual) - USD ($)	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019
Restricted Cash and Cash Equivalents, Total	$ 110,000	$ 110,000	$ 110,000

Note 5 - Prepaid Expenses - Sch

Note 5 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Prepaid research and development	$ 712,387	$ 507,733
Prepaid insurance	280,098	222,476
Professional services	278,298	108,850
Financial exchange fees	32,250
Retainer and security deposits	14,218	14,218
Prepaid rent	17,952	4,275
Other	1,917	4,792
Total prepaid expenses	$ 1,337,120	$ 862,344

Note 6 - Research and Develop_2

Note 6 - Research and Development Tax Rebate Receivable (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	May 23, 2017
Research and Development Expense, Total	$ 938,620	$ 1,451,236
Research and Development Tax Rebate Receivable	734,340		$ 739,656
Atossa Genetics AUS Pty Ltd [Member]
Research and Development Cash Rebate per Dollar				$ 0.435
Research and Development Expense, Total	$ 133,400	$ 34,700

Note 7 - Payroll Liabilities -

Note 7 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Accrued bonuses	$ 203,779	$ 646,064
Accrued vacation	179,533	170,820
Accrued payroll	83,071	82,536
Total payroll liabilities	$ 466,383	$ 899,420

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Details Textual) - USD ($)	May 08, 2020	Feb. 07, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Number of Shares Authorized to Issue (in shares)				185,000,000
Common Stock, Shares Authorized (in shares)				175,000,000		175,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.18		$ 0.18
Preferred Stock, Shares Authorized (in shares)				10,000,000		10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001		$ 0.001
Preferred Stock, Shares Issued, Total (in shares)				671		671
Proceeds from Warrant Exercises			$ 11,300,000	$ 0	$ 11,336,710
Class of Warrant or Right, Exercised During Period (in shares)					2,800,000
Stock Issued During Period, Shares, Warrant Exercised (in shares)					2,800,000
Conversion of Series B Convertible Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)				0	1,677
Conversion of Stock, Shares Issued (in shares)					476,431
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)			284		284
The 2018 Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)				1,070,028
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 4.05
At The Market Offering [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.18
Stock to be Issued, Maximum Value		$ 5,000,000
At The Market Offering [Member] | Oppenheimer & Co. Inc. [Member]
Stock Issuance Costs, Commission Fee Percent		3.00%
At The Market Offering [Member] | Oppenheimer & Co. Inc. [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)	68,098
Proceeds from Issuance of Common Stock	$ 150,253
Series A Junior Participating Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)				750,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001
Preferred Stock, Shares Issued, Total (in shares)				0
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)				4,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)				25,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.001
Sale of Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Issued, Total (in shares)				0

Note 9 - Net Loss Per Share - S

Note 9 - Net Loss Per Share - Schedule of Earnings Per Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net loss attributable to common shareholders	$ (2,947,420)	$ (4,073,307)
Weighted average common shares outstanding used to compute net loss per share, basic and diluted (in shares)	9,130,984	6,565,514
Net loss per share of common stock, basic and diluted: (in dollars per share)	$ (0.32)	$ (0.62)

Note 9 - Net Loss Per Share -_2

Note 9 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Number of potential common shares excluded (in shares)	5,569,028	4,611,845
Share-based Payment Arrangement, Option [Member]
Number of potential common shares excluded (in shares)	4,308,383	783,383
Series B Convertible Preferred Stock [Member]
Number of potential common shares excluded (in shares)	190,617	458,994
Warrant [Member]
Number of potential common shares excluded (in shares)	1,070,028	3,369,468

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accrued Income Taxes, Total	$ 0	$ 0

Note 11 - Concentration of Cr_2

Note 11 - Concentration of Credit Risk (Details Textual) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Cash, Uninsured Amount	$ 8,967,650	$ 12,316,429

Note 12 - Commitments and Con_2

Note 12 - Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating Lease, Expense	$ 13,300	$ 12,900
Operating Lease, Weighted Average Remaining Lease Term (Month)	270 days
Operating Lease, Weighted Average Discount Rate, Percent	12.00%
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year	$ 29,500
Lessee, Operating Lease, Liability, to be Paid, Year Two	12,400
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	4,500	12,900
Operating Lease, Payments	$ 14,700	$ 14,600

Note 13 - Stock Based Compens_3

Note 13 - Stock Based Compensation (Details Textual) - USD ($)	May 16, 2019	Jan. 13, 2019	Jun. 27, 2018	May 09, 2018	Apr. 12, 2018	May 18, 2016	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Sep. 28, 2010
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)
Share-based Payment Arrangement, Expense							$ 687,752		$ 275,833
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)
Adjustments to Additional Paid in Capital, Transfer of Stock-based Compensation Liability Upon Option Cancellation		$ 3,151,944							$ 3,151,944
The 2010 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	3,600,000
Share-based Payment Arrangement, Option [Member] | The 2010 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)										5,556
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)				125,000	500,000	11,111
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)							0		0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)							0		0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)							676,669
Share-based Payment Arrangement, Expense							$ 687,752		$ 275,833
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance (in shares)							476,383
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount							$ 953,046
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)							215 days
Liability Options [Member]
Share-based Payment Arrangement, Expense		$ 1,741,919							$ 1,741,919
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)			$ 1
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)			2019 years
Liability Options [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)			2,300,000
Liability Options [Member] | Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)			700,000
The 2019 Options [Member[
Share-based Payment Arrangement, Expense								$ 4,959,277
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)		$ 1.36
The 2019 Options [Member[ | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		2,300,000
The 2019 Options [Member[ | Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		800,000

Note 13 - Stock Based Compens_4

Note 13 - Stock Based Compensation - Additional Shares Authorized (Details) - shares	3 Months Ended	12 Months Ended								99 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2020
The 2010 Stock Option and Incentive Plan [Member]
Total additional shares (in shares)	365,239	233,862	106,076	12,623	7,257	5,463	4,128	2,871	2,502	740,021

Note 13 - Stock Based Compens_5

Note 13 - Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($)	Jan. 13, 2019	Mar. 31, 2020	Mar. 31, 2019
Stock compensation expense		$ 687,752	$ 275,833
General and Administrative Expense [Member]
Stock compensation expense		483,000	224,676
Research and Development Expense [Member]
Stock compensation expense		$ 204,752	51,157
Liability Options [Member]
Stock compensation expense	$ 1,741,919		1,741,919
Liability Options [Member] | General and Administrative Expense [Member]
Stock compensation expense			1,074,183
Liability Options [Member] | Research and Development Expense [Member]
Stock compensation expense			$ 667,736

Note 13 - Stock Based Compens_6

Note 13 - Stock Based Compensation - Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2020USD ($)$ / sharesshares
Granted, shares (in shares) | shares
Granted, weighted average exercise price per share (in dollars per share) | $ / shares
Forfeited, shares (in shares) | shares
Forfeited, weighted average exercise price per share (in dollars per share) | $ / shares
Expired, shares (in shares) | shares
Expired, weighted average exercise price per share (in dollars per share) | $ / shares
The 2010 Stock Option and Incentive Plan [Member]
Outstanding, shares (in shares) | shares	4,308,383
Outstanding, weighted average exercise price per share (in dollars per share) | $ / shares	$ 3.44
Outstanding, shares (in shares) | shares	4,308,383
Outstanding, weighted average exercise price per share (in dollars per share) | $ / shares	$ 3.44
Outstanding, weighted average contractual life remaining in years (Year)	8 years 292 days
Outstanding, aggreate instrinsic value | $
Exercisable, shares (in shares) | shares	3,832,000
Exercisable, Weighted average exercise price per share (in dollars per share) | $ / shares	$ 3.58
Exercisable, weighted average contractual life remaining in years (Year)	8 years 292 days
Exercisable, aggreate instrinsic value | $
Vested and expected to vest, shares (in shares) | shares	4,308,383
Vested and expected to vest, Weighted average exercise price per share (in dollars per share) | $ / shares	$ 3.44
Vested and expected to vest, weighted average contractual life remaining in years (Year)	8 years 292 days
Vested and expected to vest, aggreate instrinsic value | $

Note 13 - Stock Based Compens_7

Note 13 - Stock Based Compensation - Valuation Assumptions (Details) - Liability Options [Member]	Jan. 13, 2020$ / shares
Risk free interest rate	2.53%
Stock price (in dollars per share)	$ 1.36
Dividend yield
Minimum [Member]
Expected term (in years) (Year)	4 years 182 days
Expected volatility	121.00%
Maximum [Member]
Expected term (in years) (Year)	5 years
Expected volatility	123.00%

Note 14 - Subsequent Event (Det

Note 14 - Subsequent Event (Details Textual) - $ / shares	Apr. 09, 2020	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)
The 2010 Stock Option and Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		0	0
Subsequent Event [Member] | The 2010 Stock Option and Incentive Plan and the 2020 Performance Options Plan [Member] | Chairman of the Board, President and Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	1,500,000
Subsequent Event [Member] | The 2010 Stock Option and Incentive Plan and the 2020 Performance Options Plan [Member] | Chief Financial Officer, General Counsel and Secretary [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	590,000
Subsequent Event [Member] | The 2010 Stock Option and Incentive Plan [Member] | Chairman of the Board, President and Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	195,000
Subsequent Event [Member] | The 2010 Stock Option and Incentive Plan [Member] | Chief Financial Officer, General Counsel and Secretary [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	195,000
Subsequent Event [Member] | The 2020 Performance Options Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 1.48
Subsequent Event [Member] | The 2020 Performance Options Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	2 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Unvested Percentage for Vesting to Accelerate Under Certain Approvals	50.00%
Subsequent Event [Member] | The 2020 Performance Options Plan [Member] | Chairman of the Board, President and Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	1,305,000
Subsequent Event [Member] | The 2020 Performance Options Plan [Member] | Chief Financial Officer, General Counsel and Secretary [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	395,000